Vanguard Group
NGNE icon

Vanguard Group’s Neurogene NGNE Stock Holding History

Vanguard Group’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$13.5M Buy
656,572
+51,961
+9% +$1.29M ﹤0.01% 2804
2025
Q3 		$10.5M Sell
604,611
-5,726
-0.9% -$115K ﹤0.01% 2958
2025
Q2 		$9.12M Sell
610,337
-7,598
-1% -$119K ﹤0.01% 2954
2025
Q1 		$7.24M Buy
617,935
+49,919
+9% +$867K ﹤0.01% 3023
2024
Q4 		$13M Sell
568,016
-8,144
-1% -$303K ﹤0.01% 2810
2024
Q3 		$24.2M Buy
576,160
+12,635
+2% +$490K ﹤0.01% 2504
2024
Q2 		$20.5M Buy
563,525
+56,042
+11% +$1.98M ﹤0.01% 2559
2024
Q1 		$25.8M Buy
507,483
+457,062
+906% +$15.3M ﹤0.01% 2469
2023
Q4 		$977K Buy
50,421
+36
+0.1% +$516 ﹤0.01% 3834
2023
Q3 		$796K Sell
50,385
-156
-0.3% -$2.3K ﹤0.01% 3913
2023
Q2 		$839K Sell
50,541
-274
-0.5% -$4.49K ﹤0.01% 3952
2023
Q1 		$711K Hold
50,815
– – ﹤0.01% 4015
2022
Q4 		$517K Sell
50,815
-479
-0.9% -$4.95K ﹤0.01% 4090
2022
Q3 		$657K Sell
51,294
-4,866
-9% -$99.3K ﹤0.01% 4144
2022
Q2 		$1.16M Sell
56,160
-7,865
-12% -$192K ﹤0.01% 4038
2022
Q1 		$2.41M Sell
64,025
-15,975
-20% -$932K ﹤0.01% 3889
2021
Q4 		$7.71M Sell
80,000
-529
-0.7% -$64.4K ﹤0.01% 3373
2021
Q3 		$11.6M Buy
80,529
+850
+1% +$130K ﹤0.01% 3153
2021
Q2 		$14.7M Buy
79,679
+3,759
+5% +$832K ﹤0.01% 3004
2021
Q1 		$18.7M Buy
75,920
+18,245
+32% +$4.66M ﹤0.01% 2823
2020
Q4 		$16.3M Buy
57,675
+3,224
+6% +$788K ﹤0.01% 2739
2020
Q3 		$13.1M Buy
54,451
+4,734
+10% +$1.15M ﹤0.01% 2655
2020
Q2 		$16.5M Buy
49,717
+23,344
+89% +$6.09M ﹤0.01% 2516
2020
Q1 		$6M Buy
26,373
+280
+1% +$57.6K ﹤0.01% 2886
2019
Q4 		$6.43M Buy
26,093
+13,823
+113% +$1.38M ﹤0.01% 3078
2019
Q3 		$699K Sell
12,270
-4,859
-28% -$296K ﹤0.01% 3742
2019
Q2 		$808K Hold
17,129
– – ﹤0.01% 3733
2019
Q1 		$924K Hold
17,129
– – ﹤0.01% 3644
2018
Q4 		$740K Hold
17,129
– – ﹤0.01% 3646
2018
Q3 		$1M Buy
17,129
+484
+3% +$28.6K ﹤0.01% 3720
2018
Q2 		$882K Buy
16,645
+854
+5% +$223K ﹤0.01% 3722
2018
Q1 		$4.45M Buy
15,791
+920
+6% +$254K ﹤0.01% 3199
2017
Q4 		$3.5M Buy
14,871
+103
+0.7% +$24.1K ﹤0.01% 3258
2017
Q3 		$4.19M Buy
14,768
+644
+5% +$185K ﹤0.01% 3181
2017
Q2 		$3.97M Buy
14,124
+873
+7% +$250K ﹤0.01% 3174
2017
Q1 		$4.42M Buy
13,251
+571
+5% +$201K ﹤0.01% 3101
2016
Q4 		$4.19M Buy
12,680
+2,333
+23% +$627K ﹤0.01% 3130
2016
Q3 		$2.76M Buy
10,347
+4,821
+87% +$972K ﹤0.01% 3273
2016
Q2 		$731K Buy
5,526
+109
+2% +$17.3K ﹤0.01% 3691
2016
Q1 		$955K Buy
5,417
+702
+15% +$136K ﹤0.01% 3614
2015
Q4 		$1.18M Buy
4,715
+3,133
+198% +$824K ﹤0.01% 3570
2015
Q3 		$445K Buy
+1,582
New +$364K ﹤0.01% 3887

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Vanguard Group's NGNE Position: Q4 2025 in Review

Vanguard Group increased its Neurogene (NGNE) stake by 8.6% in Q4 2025, buying an estimated $1.29M and bringing the position to 656,572 shares worth $13.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2804.

Vanguard Group first reported a position in NGNE in Q3 2015 and has held it in 42 quarters since. The position peaked at $25.8M in Q1 2024. 93 funds tracked by Wall St. Rank hold NGNE as of Q4 2025.

  • Vanguard Group held 656,572 shares of Neurogene worth $13.5M as of Q4 2025.
  • Vanguard Group bought 51,961 Neurogene shares in Q4 2025, an estimated $1.29M.
  • Neurogene made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2804 holding.
  • Vanguard Group first reported a position in Neurogene in Q3 2015 and has held it in 42 quarters since.
  • Vanguard Group's Neurogene position peaked at $25.8M in Q1 2024.
  • 93 funds tracked by Wall St. Rank held Neurogene as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.